Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1917 1
1924 1
1927 1
1928 1
1936 1
1940 1
1941 1
1943 1
1945 1
1947 1
1948 1
1949 3
1950 3
1951 6
1952 8
1953 3
1954 6
1955 7
1956 5
1957 8
1958 6
1959 3
1960 6
1961 8
1962 9
1963 8
1964 14
1965 13
1966 14
1967 19
1968 20
1969 28
1970 44
1971 22
1972 41
1973 45
1974 53
1975 297
1976 360
1977 353
1978 370
1979 436
1980 441
1981 526
1982 603
1983 684
1984 724
1985 749
1986 793
1987 814
1988 921
1989 1135
1990 1155
1991 1157
1992 1227
1993 1376
1994 1346
1995 1402
1996 1495
1997 1520
1998 1604
1999 1766
2000 1743
2001 1805
2002 1913
2003 2068
2004 2234
2005 2479
2006 2889
2007 2896
2008 2969
2009 3099
2010 3394
2011 3683
2012 3869
2013 4150
2014 4613
2015 4697
2016 4961
2017 5217
2018 5472
2019 5693
2020 6743
2021 7584
2022 7292
2023 7177
2024 2187

Text availability

Article attribute

Article type

Publication date

Search Results

112,391 results

Results by year

Filters applied: . Clear all
Page 1
Norepinephrine vs Vasopressin: Which Vasopressor Should Be Discontinued First in Septic Shock? A Meta-Analysis.
Wu Z, Zhang S, Xu J, Xie J, Huang L, Huang Y, Yang Y, Qiu H. Wu Z, et al. Shock. 2020 Jan;53(1):50-57. doi: 10.1097/SHK.0000000000001345. Shock. 2020. PMID: 31008869
Moreover, there is controversial data guiding clinicians on how to discontinue vasopressors for septic shock patients who are receiving a combination therapy of NE and VP. ...Studies were limited to adult patients with septic shock who received concomitant NE and VP …
Moreover, there is controversial data guiding clinicians on how to discontinue vasopressors for septic shock patients who are receivi …
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.
Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, Roux C, Törring O, Valter I, Wang AT, Brown JP. Cummings SR, et al. J Bone Miner Res. 2018 Feb;33(2):190-198. doi: 10.1002/jbmr.3337. Epub 2017 Nov 22. J Bone Miner Res. 2018. PMID: 29105841 Free article. Clinical Trial.
Of 1001 participants who discontinued denosumab during FREEDOM or Extension, the vertebral fracture rate increased from 1.2 per 100 participant-years during the on-treatment period to 7.1, similar to participants who received and then discontinued placebo (n …
Of 1001 participants who discontinued denosumab during FREEDOM or Extension, the vertebral fracture rate increased from 1.2 per 100 p …
Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention-deficit/hyperactivity disorder.
Nasser A, Kosheleff AR, Hull JT, Liranso T, Qin P, Busse GD, Fava M, Maletic V, Rubin J, Lopez F. Nasser A, et al. Int J Clin Pract. 2021 Aug;75(8):e14330. doi: 10.1111/ijcp.14330. Epub 2021 May 26. Int J Clin Pract. 2021. PMID: 33971070 Free PMC article.
AIMS: When clinicians evaluate potential medications for their patients, they must weigh the probability of a treatment's benefits against the possible risks. To this end, the present analyses evaluate the novel nonstimulant viloxazine extended-release (viloxazine E …
AIMS: When clinicians evaluate potential medications for their patients, they must weigh the probability of a treatment's bene …
When is it safe to discontinue AED treatment?
Camfield P, Camfield C. Camfield P, et al. Epilepsia. 2008 Dec;49 Suppl 9:25-8. doi: 10.1111/j.1528-1167.2008.01923.x. Epilepsia. 2008. PMID: 19087114 Free article. Review.
When people with epilepsy become seizure-free with daily antiepileptic drug (AED) management, there is a very individual decision to be made about discontinuing this treatment. After 1-6 years of seizure-freedom, it is estimated that 69% of children and 61% of adult …
When people with epilepsy become seizure-free with daily antiepileptic drug (AED) management, there is a very individual decision to be made …
'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue.
Clay S, Treloar C, Degenhardt L, Grebely J, Christmass M, Gough C, Hayllar J, McDonough M, Henderson C, Crawford S, Farrell M, Marshall A. Clay S, et al. Int J Drug Policy. 2023 May;115:104002. doi: 10.1016/j.drugpo.2023.104002. Epub 2023 Mar 30. Int J Drug Policy. 2023. PMID: 37003194 Free article.
However, there has been little research that focuses on the lived experience of people receiving depot buprenorphine treatment and reasons for why people decide to discontinue. The aim of this study was to explore what it is like to receive depot buprenorphine and t …
However, there has been little research that focuses on the lived experience of people receiving depot buprenorphine treatment and re …
Patient Preferences in Topical Psoriasis Treatment.
Curcio A, Kontzias C, Gorodokin B, Feldman S, Kircik L. Curcio A, et al. J Drugs Dermatol. 2023 Apr 1;22(4):326-332. doi: 10.36849/JDD.7372. J Drugs Dermatol. 2023. PMID: 37026884
The formulation attributes rated most important were application feel (55.2%), non-staining (49.9%), quick absorption (46.7%), non-sticky texture (39.7%), ease of application (28.5%), no unpleasant smell (22.4%), non-greasy (16.8%), works quickly (14.1%), absent sting or burn (10 …
The formulation attributes rated most important were application feel (55.2%), non-staining (49.9%), quick absorption (46.7%), non-sticky te …
Update on the right to refuse antipsychotic medication.
Williams KG. Williams KG. DICP. 1991 Jul-Aug;25(7-8):849-52. doi: 10.1177/106002809102500722. DICP. 1991. PMID: 11659419
The legal history and current developments in the right to refuse antipsychotic medication are reviewed. In Washington v. Harper the US Supreme Court analyzed the right to refuse antipsychotic medication under the due process clause of th …
The legal history and current developments in the right to refuse antipsychotic medication are reviewed. In Washington …
Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature.
Chen DY, Lau CS, Elzorkany B, Hsu PN, Praprotnik S, Vasilescu R, Marshall L, Llamado L. Chen DY, et al. Int J Rheum Dis. 2018 Feb;21(2):362-372. doi: 10.1111/1756-185X.13238. Epub 2017 Dec 4. Int J Rheum Dis. 2018. PMID: 29205904 Review.
AIM: To review the published studies that dose down and then discontinue biologic therapy in patients with rheumatoid arthritis (RA), particularly concerning the criteria for such dosing and the impact on clinical outcomes. ...CONCLUSION: In patients who have achiev …
AIM: To review the published studies that dose down and then discontinue biologic therapy in patients with rheumatoid arthriti …
The decision to continue or discontinue treatment: experiences and beliefs of users of selective serotonin-reuptake inhibitors in the initial months--a qualitative study.
van Geffen EC, Hermsen JH, Heerdink ER, Egberts AC, Verbeek-Heida PM, van Hulten R. van Geffen EC, et al. Res Social Adm Pharm. 2011 Jun;7(2):134-50. doi: 10.1016/j.sapharm.2010.04.001. Epub 2010 Jun 7. Res Social Adm Pharm. 2011. PMID: 21272543
Eighteen patients, older than 18 years, were interviewed 3 months after starting SSRI treatment prescribed by a general practitioner (GP), 9 of whom had discontinued (discontinuers) and 9 of whom continued treatment (continuers). ...Discontinuers
Eighteen patients, older than 18 years, were interviewed 3 months after starting SSRI treatment prescribed by a general practitioner …
Factors influencing patient decisions to initiate and discontinue subcutaneous testosterone pellets (Testopel) for treatment of hypogonadism.
Smith RP, Khanna A, Coward RM, Rajanahally S, Kovac JR, Gonzales MA, Lipshultz LI. Smith RP, et al. J Sex Med. 2013 Sep;10(9):2326-33. doi: 10.1111/jsm.12226. Epub 2013 Jul 16. J Sex Med. 2013. PMID: 23859250
Convenience (68.8%) was the most important factor in patients' decision to start STP, while cost of the previous form of TRT (14.7%) was least important. At the time of the survey, 32 men (28.3%) had discontinued STP therapy. Cost of therapy (50%) was the pri …
Convenience (68.8%) was the most important factor in patients' decision to start STP, while cost of the previous form of TRT (14.7%) was lea …
112,391 results
You have reached the last available page of results. Please see the User Guide for more information.